Lipid composition and fluidity of the human immunodeficiency virus.
about
Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2Amphotropic murine leukaemia virus envelope protein is associated with cholesterol-rich microdomainsThe broad anti-viral agent glycyrrhizin directly modulates the fluidity of plasma membrane and HIV-1 envelopeHuman immunodeficiency virus infection of T cells and monocytes proceeds via receptor-mediated endocytosisHIV-1 fusion inhibitor peptides enfuvirtide and T-1249 interact with erythrocyte and lymphocyte membranesRetroviral vectors for clinical immunogene therapy are stable for up to 9 years.Transcytosis of HIV-1 through vaginal epithelial cells is dependent on trafficking to the endocytic recycling pathway.Evidence that Gag facilitates HIV-1 envelope association both in GPI-enriched plasma membrane and detergent resistant membranes and facilitates envelope incorporation onto virions in primary CD4+ T cells.Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions.Biochemical consequences of a mutation that controls the cholesterol dependence of Semliki Forest virus fusionMolecular dynamics exploration of poration and leaking caused by Kalata B1 in HIV-infected cell membrane compared to host and HIV membranesMultimerization of human immunodeficiency virus type 1 Gag promotes its localization to barges, raft-like membrane microdomainsHIV-1, lipid rafts, and antibodies to liposomes: implications for anti-viral-neutralizing antibodies.Effect of heat on viral protein production and budding in cultured mammalian cells.Palmitoylation of the murine leukemia virus envelope protein is critical for lipid raft association and surface expression.The HIV lipidome: a raft with an unusual compositionInhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.Cholesterol-dependent membrane fusion induced by the gp41 membrane-proximal external region-transmembrane domain connection suggests a mechanism for broad HIV-1 neutralization.Palmitoylation of the HIV-1 envelope glycoprotein is critical for viral infectivitySterol-rich plasma membrane domains in fungi.Identification of mumps virus protein and lipid composition by mass spectrometry.A molecular tweezer antagonizes seminal amyloids and HIV infection.The Trojan exosome hypothesisLipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes.Characterization and role of lentivirus-associated host proteins.The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine designConformational mapping of the N-terminal peptide of HIV-1 gp41 in lipid detergent and aqueous environments using 13C-enhanced Fourier transform infrared spectroscopyThe broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5.Structural and functional properties of peptides based on the N-terminus of HIV-1 gp41 and the C-terminus of the amyloid-beta protein.Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency.Impact of HIV-1 Membrane Cholesterol on Cell-Independent Lytic Inactivation and Cellular Infectivity.Amphipathic domains in the C terminus of the transmembrane protein (gp41) permeabilize HIV-1 virions: a molecular mechanism underlying natural endogenous reverse transcription.The lipidomes of vesicular stomatitis virus, semliki forest virus, and the host plasma membrane analyzed by quantitative shotgun mass spectrometry.Maturation of the Gag core decreases the stability of retroviral lipid membranes.Early events of HIV-1 infection: can signaling be the next therapeutic target?Retroviral matrix and lipids, the intimate interaction.Role of lipids in virus replicationHIV-1 assembly, budding, and maturation.Cholesterol-conjugated peptide antivirals: a path to a rapid response to emerging viral diseases.A first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol.
P2860
Q21559418-75B528F8-F032-4268-A727-9F22D7D320AAQ24795918-41644152-CFA5-4F60-9D37-68AAFEF2CE5FQ27472782-7A3B4874-F1B4-44B0-BEE4-4A19275575B0Q27482398-9BFB82C8-8427-4F9F-9F97-78E60FCDC48FQ28473380-B1DDBB90-9772-46D2-BE2C-C609375FD5DDQ33315244-7220EF10-633A-407F-8FCF-4DC834852AA3Q33618602-D6397960-0F1C-43EE-939C-693A9871991FQ33645234-366D0F99-7CEA-4996-B2A0-A3439704C8BFQ33667654-60347EA9-DE94-4A84-AF32-51AF2AFF8E7DQ33797087-B1264627-28E7-4682-A6F9-9C2E9BC0270AQ33804191-CC0273D6-B724-4855-8286-8DAE2B8BFC03Q33853532-4865A9E9-A5AC-44B5-A9D7-F071A3001341Q34001144-A4E20F35-CDC0-462A-A650-564E051AC8A7Q34314955-664A410B-E682-4096-AA0E-3AF0CC2B611EQ34359777-ABF05514-9955-499F-A393-6A6C94222719Q34479764-02B673D1-0719-4F27-84A9-7D614A234C77Q34517381-79A97D15-2FF0-43BB-814D-8F7F437F0FB5Q34594591-9A116052-E377-4D63-9D0C-2548DFB7CCFCQ35566715-FE57675C-A8E5-47F7-9940-54B6216EB286Q35855072-74DDC52E-2C9C-40E0-AC74-D1E79C9B62A9Q35894459-5C5EB722-B627-48A8-B678-FB1EEC1B6D08Q35954283-86A4AC50-CAA4-495C-AE9D-F77515FA1E61Q35976953-9F9F0226-CB43-4DC4-8EF9-4E1BCC7F15F2Q36342211-82B190CF-7341-412C-AAAD-896A3327C75CQ36412305-B806931F-DF28-4CEC-A69A-D7A5DB075497Q36497712-9771A57C-0B86-4A42-8EE3-36664607E88BQ36519512-A54DC12A-6E75-4EF1-9C87-D6B318E55BF4Q36898696-DEB1F13F-2BEF-4528-99A8-DDB61365628CQ37071276-8122A644-9745-46C2-B7EC-BF3A8CE48D84Q37153758-1821FB72-2B8A-400D-813B-777999568FB4Q37183472-B7165717-C3DD-4E08-8F3B-C700D6332686Q37242308-34B444E8-A4B3-494D-AE1E-D344C4492678Q37275121-FB3F308D-2112-4E0D-8AFF-867A53F79CA6Q37359745-B4BF25F8-2158-4DE5-BDD4-BB9D27A00774Q37849655-209F593D-E20A-4408-9DE1-A9A1912C06B5Q37850839-A038EA89-CF2A-48CB-A724-869E09C7D363Q37882865-DB34931A-BB7E-4EAD-95D8-817FE16BAC8CQ38023864-1196F829-E1D8-4F8C-978C-48E5C183B09DQ38261556-8A237298-8DBB-4930-A6BF-23819C60F182Q38607635-906CB707-4BF0-44B6-84DF-9EE7EB4C0F30
P2860
Lipid composition and fluidity of the human immunodeficiency virus.
description
1988 nî lūn-bûn
@nan
1988 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Lipid composition and fluidity of the human immunodeficiency virus.
@ast
Lipid composition and fluidity of the human immunodeficiency virus.
@en
Lipid composition and fluidity of the human immunodeficiency virus.
@nl
type
label
Lipid composition and fluidity of the human immunodeficiency virus.
@ast
Lipid composition and fluidity of the human immunodeficiency virus.
@en
Lipid composition and fluidity of the human immunodeficiency virus.
@nl
prefLabel
Lipid composition and fluidity of the human immunodeficiency virus.
@ast
Lipid composition and fluidity of the human immunodeficiency virus.
@en
Lipid composition and fluidity of the human immunodeficiency virus.
@nl
P2093
P2860
P356
P1476
Lipid composition and fluidity of the human immunodeficiency virus.
@en
P2093
P2860
P304
P356
10.1073/PNAS.85.3.900
P407
P577
1988-02-01T00:00:00Z